Researchers proposed to develop two Cu (II) complexes based on the His242 residue of the IIA subdomain of the human serum albumin (HSA) carrier (13 and 14, Scheme 2) (Qi et al., 2016) to improve the delivery efficiency, anti-cancer activity and selectivity of anti-cancer metal preparations in vivo. The gene discussed is ALB; the disease is cancer.